Facebook Page Lands Drugmaker In Hot Water With FDA

Law360, New York (March 12, 2014, 6:08 PM EDT) -- The U.S. Food and Drug Administration on Wednesday published a rare rebuke to a drugmaker over improper promotion on social media, chastising Switzerland-based IBSA Institut Biochimique SA over a Facebook page that allegedly didn’t disclose any risks for a drug that has a black box warning.

In its so-called untitled letter, which represents a relatively mild form of discipline, the FDA accused IBSA of creating a Facebook page for hypothyroidism drug Tirosint that failed to mention anything about potential side effects.

A screen grab provided by...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.